(Total Views: 472)
Posted On: 05/31/2025 1:41:55 PM
Post# of 153899
Claim vs Reality
“Leronlimab patents are owned by Progenics & AbbVie, not CYDY”
❌ Misleading—Progenics licensed it to CYDY in 2012; AbbVie has no involvement
Leronlimab is “nothing special”
❌ False—CCR5 targeting mAb with unique safety and multi-indication potential
Progenics tried to sell it and failed
❌ False—they licensed it and moved on; no evidence of attempted sale
CYDY couldn’t get a partner
⚠️ Partly true—but due to management/regulatory issues, not lack of drug value
I believe your statements about Leronlimab and CytoDyn are inaccurate and misleading. Leronlimab is not “owned” by AbbVie or Progenics—Progenics licensed the rights to CytoDyn in 2012, and AbbVie has no known involvement. It’s also misleading to say the drug is “nothing special,” as Leronlimab is a CCR5-targeting monoclonal antibody with demonstrated promise in HIV, cancer, and other conditions, supported by clinical data and a strong safety profile. Progenics did not try to sell the drug for years—they licensed it, which is common in biotech, and moved on to other priorities. While CytoDyn has certainly struggled with leadership and regulatory issues, that doesn’t equate to the science being invalid. If your intention is to share honest concerns, that’s fair—but if you’re pushing a narrative built on outdated or false assumptions, it does a disservice to others doing real due diligence.
“Leronlimab patents are owned by Progenics & AbbVie, not CYDY”
❌ Misleading—Progenics licensed it to CYDY in 2012; AbbVie has no involvement
Leronlimab is “nothing special”
❌ False—CCR5 targeting mAb with unique safety and multi-indication potential
Progenics tried to sell it and failed
❌ False—they licensed it and moved on; no evidence of attempted sale
CYDY couldn’t get a partner
⚠️ Partly true—but due to management/regulatory issues, not lack of drug value
I believe your statements about Leronlimab and CytoDyn are inaccurate and misleading. Leronlimab is not “owned” by AbbVie or Progenics—Progenics licensed the rights to CytoDyn in 2012, and AbbVie has no known involvement. It’s also misleading to say the drug is “nothing special,” as Leronlimab is a CCR5-targeting monoclonal antibody with demonstrated promise in HIV, cancer, and other conditions, supported by clinical data and a strong safety profile. Progenics did not try to sell the drug for years—they licensed it, which is common in biotech, and moved on to other priorities. While CytoDyn has certainly struggled with leadership and regulatory issues, that doesn’t equate to the science being invalid. If your intention is to share honest concerns, that’s fair—but if you’re pushing a narrative built on outdated or false assumptions, it does a disservice to others doing real due diligence.
(6)
(0)
LETS GO!!!
